Circulating Epstein–Barr virus DNA as a precision biomarker in nasopharyngeal carcinoma: from risk stratification to real-time treatment adaptation and disease surveillance

EBV DNA is evolving from a static biomarker into an operational tool for precision oncology in NPC. Its integration enables biologically informed risk stratification, dynamic response assessment, and adaptive treatment strategies, with important implications for personalized management of NPC.